Literature DB >> 11396870

Therapeutic continuity in Alzheimer's disease: switching patients to galantamine. Panel discussion: recommendations for prescribers.

J C Morris1, M R Farlow, S H Ferris, A F Kurz, A Maelicke, L Rasmusen, D Wilkinson, B Yan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11396870     DOI： 10.1016/s0149-2918(01)80166-1

Source DB:  PubMed          Journal:  Clin Ther        ISSN： 0149-2918            Impact factor:   3.393


× No keyword cloud information.
  5 in total

Review 1.  Advances in the pharmacotherapy of Alzheimer's disease.

Authors:  Serge Gauthier
Journal:  CMAJ       Date:  2002-03-05       Impact factor: 8.262

2.  Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease.

Authors:  Peter Johannsen; Eric Salmon; Harald Hampel; Yikang Xu; Sharon Richardson; Suzanne Qvitzau; Rachel Schindler
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 3.  Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.

Authors:  Carole Parsons; Wei Yin Lim; Clement Loy; Bernadette McGuinness; Peter Passmore; Stephanie A Ward; Carmel Hughes
Journal:  Cochrane Database Syst Rev       Date:  2021-02-03

Review 4.  Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease.

Authors:  Nazem Bassil; George T Grossberg
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

5.  Effect of galantamine on platelet functions in healthy elderly people.

Authors:  Ahmet Turan Isik; Ergun Bozoglu; Kursat Kaptan; Turgay Celik
Journal:  Indian J Med Res       Date:  2013-05       Impact factor: 2.375
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.